Figure 1. Association between the modified Vesikari severity score of
gastroenteritis and log10 challenge dose of SMV inoculum
(genome copies). Simple linear regressions were performed for subjects
in two challenge studies and fitted line (in blue) and confidence
interval (in gray) are presented.
References
1. Zhang S, Chen TH, Wang J, Dong C, Pan J, Moe C, et al. Symptomatic
and asymptomatic infections of rotavirus, norovirus, and adenovirus
among hospitalized children in Xi’an, China. J Med Virol. 2011
Aug;83(8):1476-84.
2. Kirby AE, Kienast Y, Zhu W, Barton J, Anderson E, Sizemore M, et al.
Norovirus Seroprevalence among Adults in the United States: Analysis of
NHANES Serum Specimens from 1999-2000 and 2003-2004. Viruses. 2020 Feb
5;12(2).
3. Hall AJ, Lopman BA, Payne DC, Patel MM, Gastanaduy PA, Vinje J, et
al. Norovirus disease in the United States. Emerg Infect Dis. 2013
Aug;19(8):1198-205.
4. Barclay L, Park GW, Vega E, Hall A, Parashar U, Vinje J, et al.
Infection control for norovirus. Clin Microbiol Infect. 2014
Aug;20(8):731-40.
5. Chhabra P, de Graaf M, Parra GI, Chan MC, Green K, Martella V, et al.
Updated classification of norovirus genogroups and genotypes. J Gen
Virol. 2019 Oct;100(10):1393-406.
6. Vinje J. Advances in laboratory methods for detection and typing of
norovirus. J Clin Microbiol. 2015 Feb;53(2):373-81.
7. Lindesmith L, Moe C, Marionneau S, Ruvoen N, Jiang X, Lindblad L, et
al. Human susceptibility and resistance to Norwalk virus infection. Nat
Med. 2003 May;9(5):548-53.
8. Hutson AM, Airaud F, LePendu J, Estes MK, Atmar RL. Norwalk virus
infection associates with secretor status genotyped from sera. J Med
Virol. 2005 Sep;77(1):116-20.
9. Rouphael N, Beck A, Kirby AE, Liu P, Natrajan MS, Lai L, et al.
Dose-Response of a Norovirus GII.2 Controlled Human Challenge Model
Inoculum. J Infect Dis. 2022 Feb 8.
10 Frenck R, Bernstein DI, Xia M, Huang P, Zhong W, Parker S, et al.
Predicting susceptibility to norovirus GII.4 by use of a challenge model
involving humans. J Infect Dis. 2012 Nov;206(9):1386-93.
11. Lindesmith L, Moe C, Lependu J, Frelinger JA, Treanor J, Baric RS.
Cellular and humoral immunity following Snow Mountain virus challenge. J
Virol. 2005 Mar;79(5):2900-9.
12. Dolin R, Reichman RC, Roessner KD, Tralka TS, Schooley RT, Gary W,
et al. Detection by immune electron microscopy of the Snow Mountain
agent of acute viral gastroenteritis. J Infect Dis. 1982
Aug;146(2):184-9.
13. Teunis PFM, Le Guyader FS, Liu P, Ollivier J, Moe CL. Noroviruses
are highly infectious but there is strong variation in host
susceptibility and virus pathogenicity. Epidemics. 2020 Sep;32:100401.
14. Ruuska T, Vesikari T. Rotavirus disease in Finnish children: use of
numerical scores for clinical severity of diarrhoeal episodes. Scand J
Infect Dis. 1990;22(3):259-67.
15. Liu P, Rahman M, Leon J, Moe C. Less severe clinical symptoms of
Norwalk virus 8fIIb inoculum compared to its precursor 8fIIa from human
challenge studies. J Med Virol. 2021 Jun;93(6):3557-63.
16. Kirby AE, Shi J, Montes J, Lichtenstein M, Moe CL.
Disease course and
viral shedding in experimental Norwalk virus and Snow Mountain virus
infection. J Med Virol. 2014;86(12):2055-64.
17. Steyer A, Konte T, Sagadin M, Kolenc M, Skoberne A, Germ J, et al.
Intrahost Norovirus Evolution in Chronic Infection Over 5 Years of
Shedding in a Kidney Transplant Recipient. Front Microbiol. 2018;9:371.
18. Davis A, Cortez V, Grodzki M, Dallas R, Ferrolino J, Freiden P, et
al. Infectious Norovirus Is Chronically Shed by Immunocompromised
Pediatric Hosts. Viruses. 2020 Jun 5;12(6).
19. Liu P, Hsiao HM, Jaykus LA, Moe C. Quantification of Norwalk virus
inocula: Comparison of endpoint titration and real-time reverse
transcription-PCR methods. J Med Virol. 2010 Sep;82(9):1612-6.
20. Swanstrom J, Lindesmith LC, Donaldson EF, Yount B, Baric RS.
Characterization of blockade antibody responses in GII.2.1976 Snow
Mountain virus-infected subjects. J Virol. 2014 Jan;88(2):829-37.
21. Nam JH, Shim SM, Song EJ, Espano E, Jeong DG, Song D, et al. Rapid
virulence shift of an H5N2 avian influenza virus during a single passage
in mice. Arch Virol. 2017 Oct;162(10):3017-24.
22. Jegede A, Fu Q, Berhane Y, Lin M, Kumar A, Guan J. H9N2 avian
influenza virus retained low pathogenicity after serial passage in
chickens. Can J Vet Res. 2018 Apr;82(2):131-38.
23. Ren SY, Wang WB, Gao RD, Zhou AM. Omicron variant (B.1.1.529) of
SARS-CoV-2: Mutation, infectivity, transmission, and vaccine resistance.
World J Clin Cases. 2022 Jan 7;10(1):1-11.